A phase III randomized study of cisplatin (NSC 119875) and Taxol (paclitaxel) (NSC 125973) with interval secondary cytoreduction versus cisplatin and paclitaxel in patients with suboptimal stage III and IV epithelial ovarian carcinoma

Trial Profile

A phase III randomized study of cisplatin (NSC 119875) and Taxol (paclitaxel) (NSC 125973) with interval secondary cytoreduction versus cisplatin and paclitaxel in patients with suboptimal stage III and IV epithelial ovarian carcinoma

Completed
Phase of Trial: Phase III

Latest Information Update: 20 May 2010

At a glance

  • Drugs Cisplatin (Primary) ; Paclitaxel (Primary)
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 May 2010 Actual end date (March 2010) added as reported by ClinicalTrials.gov.
    • 12 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top